EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines
| Autor: | Rita de Cassia Sinigaglia, Giselle Pidde, Leny Toma, Bruno Ramos Salu, Rodrigo Aquino Castro, Ana Marisa Chudzinski-Tavassi, Fabricio Pereira Batista, Camila Ramalho Bonturi, Maria Luiza Vilela Oliva, Denise V. Tambourgi, Camila Bonazza, Yara Aparecida Lobo, Carolina M. Vicente, Miryam Paola Alvarez-Flores |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Cell Survival Triple Negative Breast Neoplasms medicine.disease_cause Collagen Type I Proinflammatory cytokine Metastasis 03 medical and health sciences 0302 clinical medicine Breast cancer Cell Movement Cell Line Tumor Humans Medicine Protein kinase B Triple-negative breast cancer Cell Proliferation Glycosaminoglycans business.industry Cancer Fabaceae Cell cycle medicine.disease Matrix Metalloproteinases 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research Cytokines Female Trypsin Inhibitors business Carcinogenesis |
| Zdroj: | Cancer Letters. 491:108-120 |
| ISSN: | 0304-3835 |
| Popis: | Breast cancer is the most common malignant tumor among women worldwide, and triple-negative breast cancer is the most aggressive type of breast cancer, which does not respond to hormonal therapies. The protease inhibitor, EcTI, extracted from seeds of Enterolobium contortisiliquum, acts on the main signaling pathways of the MDA-MB-231 triple-negative breast cancer cells. This inhibitor, when bound to collagen I of the extracellular matrix, triggers a series of pathways capable of decreasing the viability, adhesion, migration, and invasion of these cells. This inhibitor can interfere in the cell cycle process through the main signaling pathways such as the adhesion, Integrin/FAK/SRC, Akt, ERK, and the cell death pathway BAX and BCL-2. It also acts by reducing the main inflammatory cytokines such as TGF-α, IL-6, IL-8, and MCP-1, besides NFκB, a transcription factor, responsible for the aggressive and metastatic characteristics of this type of tumor. Thus, the inhibitor was able to reduce the main processes of carcinogenesis of this type of cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect